Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Celecoxib + Interferon alpha-2b + Rintatolimod |
Synonyms | |
Therapy Description |
Celebra (celecoxib) is a COX-2 inhibitor FDA approved as an anti-inflammatory agent and for colorectal polyp reduction (FDA.gov). Celebra (celecoxib) also promotes apoptosis of tumor cells (PMID: 17909047). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Celecoxib | Celecoxib is a COX-2 inhibitor that blocks inflammatory response and has anti-angiogenic and anti-proliferative activities (PMID: 31726219), which may lead to tumor growth inhibition (PMID: 17909047, PMID: 16740761). | |||
Interferon alpha-2b | Intron A | Alfatronol|Alfatronol|interferon alfa-2b|Sch 30500 | ||
Rintatolimod | Ampligen|Atvogen|Poly(I).Poly(c12,U) | Rintatolimod (Ampligen) is a synthetic dsRNA molecule that activates TLR3 and other interferon-induced proteins, which may result in increased anti-tumor immune response (PMID: 27045557, PMID: 19200817). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03403634 | Phase I | Celecoxib + Interferon alpha-2b + Rintatolimod | Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | Completed | USA | 0 |